BG1 Antibody

What is the BG1 antibody and what epitope does it target?

BG1 is a broadly neutralizing antibody (bNAb) that targets the V1V2 loops at the apex of the HIV-1 envelope (Env) trimer. It was isolated from an HIV-1 controller who developed elite levels of HIV-1 neutralizing activity . BG1 binds specifically to the V1V2 region and is sensitive to mutations at the N160 glycosylation site, as demonstrated by its inability to neutralize HIV-1YU2 variants with the N160K mutation . BG1 represents one of several classes of bNAbs targeting different epitopes on HIV-1 Env, and is notable for being the first antibody in the V1V2-targeting class to be isolated from a clade B-infected donor .

How does BG1 compare to other V1V2-targeting antibodies in terms of neutralization breadth and potency?

BG1 demonstrates moderate breadth and potency compared to other V1V2-targeting antibodies:

BG1's potency is similar to members of the VRC26 antibody family but less potent than PG9/16 and PGDM1400 bNAbs . When tested against a panel of 118 diverse HIV-1 strains, BG1 neutralized approximately 37% of viruses .

When was BG1 discovered and how was it isolated?

BG1 was discovered prior to 2010 and was isolated from an HLA-B57*01 HIV-1 controller who maintained low viral loads for 30 years after infection. The isolation method involved single B cell sorting using various HIV-1 baits including 2CC core, gp140YU2, a mixture of gp14092UG37.8 (clade A) + gp140CZA79012 (clade C), and BG505 SOSIP.664 . Transcripts for BG1 were detected in samples from both 2010 and 2013, indicating that BG1 developed earlier than some other antibodies (like BG18) from the same donor .

What is unique about BG1's binding mode to HIV-1 Env?

BG1 exhibits a distinct binding mode that differentiates it from other V1V2-targeting antibodies:

• Stoichiometry: Two BG1 Fabs bind per Env trimer, creating an asymmetric recognition of the V1V2 loops at the trimer apex .

• CDRH3 characteristics: Unlike other V1V2 bNAbs that use long, protruding CDRH3 loops to penetrate the glycan shield, BG1 has a relatively compact CDRH3 (22 residues) that does not extend notably beyond the antigen-binding site surface .

• Asymmetric binding pattern: The two BG1 Fabs that bind to Env (designated BG1_A and BG1_B) show distinct angles of approach when complexed with the trimer .

• Interaction with glycans: BG1 interacts with the Asn156gp120 and Asn160gp120 glycans and is more heavily reliant on glycan contacts than other V1V2 bNAbs .

This unique binding mode was revealed through cryo-EM studies at 6.2 Å resolution, showing a previously unseen form of recognition of the V1V2 epitope .

How does the CDRH3 of BG1 differ from other V1V2-targeting bNAbs?

The CDRH3 of BG1 shows several distinctive features compared to other V1V2-targeting antibodies:

The relatively compact nature of BG1's CDRH3 represents a distinct approach to V1V2 epitope recognition that does not require the protruding CDRH3 seen in other antibodies of this class .

What techniques have been used to determine the binding properties of BG1?

Several complementary techniques have been employed to characterize BG1's binding properties:

• Cryo-electron microscopy (cryo-EM): Used to determine the structure of BG1 Fab in complex with HIV-1 Env trimer at 6.2 Å resolution, revealing the asymmetric binding mode of two BG1 Fabs per trimer .

• X-ray crystallography: Used to solve the structure of unbound BG1 Fab at 2.0 Å resolution, revealing details of the CDRH3 conformation .

• Neutralization assays: TZM-bl cell-based assays using HIV-1YU2 variants with epitope-specific mutations to map BG1's binding site, showing sensitivity to the N160K mutation .

• Competitive ELISA: Used to confirm epitope mapping results for BG1 .

• Biophysical binding studies: Employed to determine stoichiometry of binding to HIV-1 Env trimer .

• Single-genome sequencing: Applied to track the evolution of viral sequences over time in relation to the development of bNAbs like BG1 .

These methodologies provide complementary information about structural features, binding interactions, and neutralization properties of BG1.

How can researchers determine if BG1 binds bivalently to HIV-1 Env trimers?

To investigate whether BG1 IgG binds bivalently to Env trimers (which would result in increased avidity due to intra-spike crosslinking), researchers can:

• Compare neutralization potencies of IgG and Fab forms: Calculate the molar neutralization ratio (MNR), defined as [IC50 Fab (nM)/IC50 IgG (nM)]. A ratio of 2.0 would be expected in the absence of avidity effects, while substantially higher ratios suggest bivalent binding .

• Control comparisons: Compare the MNR of BG1 with antibodies known not to bind bivalently, such as PG9/PG16 (which bind one Fab per trimer) and CD4bs bNAbs like VRC01 and 3BNC60 .

• Positive control: Include a known bivalent antibody construct (e.g., a bivalent form like 3BNC60 joined by a double-stranded DNA linker) which shows substantially higher MNR values .

Research indicates that BG1 IgG likely does not bind bivalently to Env trimers during neutralization, as evidenced by its geometric mean MNR of 8.4, which is comparable to antibodies known not to bind bivalently (PG9: 6.0, PG16: 10.3, VRC01: 4.8, 3BNC60: 8.1) and much lower than bivalent constructs (mean MNR of 141) .

How can BG1 be used in HIV-1 vaccine design strategies?

BG1's unique binding characteristics offer several opportunities for HIV-1 vaccine design:

The molecular details of BG1's interaction with Env provide valuable information for rational design of immunogens targeting the V1V2 epitope with potentially simpler antibody responses.

What are the challenges in eliciting BG1-like antibodies through vaccination?

Several challenges exist in eliciting BG1-like antibodies through vaccination:

• Glycan interference: BG1 binding is sensitive to glycosylation at position Asn130gp120, requiring immunogen designs that address this potential interference .

• Lower potency: While BG1 represents a potentially easier-to-elicit antibody class due to its shorter CDRH3, it shows lower potency compared to other V1V2 bNAbs (e.g., PG9/16, PGDM1400) , suggesting potential tradeoffs between ease of elicitation and neutralization potency.

• Asymmetric recognition: The asymmetric binding mode of BG1 (two Fabs per trimer) presents unique challenges for immunogen design, as most immunogen strategies have focused on epitopes recognized by antibodies with different stoichiometries .

• Capturing rare conformations: The binding model for BG1 suggests it may capture conformations of Env where glycans are shifted away from their typical positions , which may be difficult to stabilize in immunogen designs.

• Maturation pathway: While BG1 may not require the extensive affinity maturation seen with some bNAbs, designing sequential immunization strategies to guide B-cell development toward BG1-like responses remains challenging.

These challenges require careful immunogen design strategies that consider both the structural features of the BG1 epitope and the developmental pathway of B-cell responses.

How does BG1 coexist with HIV-1 in elite controllers?

The coexistence of BG1 with HIV-1 in elite controllers provides insights into virus-antibody dynamics:

• Viral diversity and antibody pressure: In the HIV-1 controller from whom BG1 was isolated, single-genome sequencing over a 9-year period revealed diverse circulating viruses, with 88.5% (31 of 35) remaining sensitive to at least one of the temporally coincident autologous bNAbs (including BG1) and the individual's serum .

• Combined antibody effects: BG1 coexisted with other bNAbs (BG18 and NC37) targeting non-overlapping sites, providing broader coverage against diverse viral variants and potentially contributing to viral control .

• In vivo efficacy: Studies in humanized mice showed that combinations of bNAbs including BG1 can suppress HIV-1 replication and maintain low-level viremia, suggesting mechanisms by which elite controllers may maintain viral suppression .

• Temporal dynamics: Transcripts for BG1 were detected in samples from both 2010 and 2013, indicating persistence of this antibody lineage over time, while other antibodies (like BG18) emerged later , suggesting ongoing evolution of the antibody response.

This research challenges the conventional view that bNAbs that develop during chronic infection are unable to control HIV-1 in the individual who develops them, suggesting that certain combinations of bNAbs may contribute to viral control in elite controllers .

What controls should be included when evaluating BG1 binding or neutralization?

When studying BG1 binding or neutralization, appropriate controls should include:

• Epitope mutants: HIV-1 variants with mutations in key residues of the V1V2 epitope, particularly those affecting the N160 glycosylation site (e.g., N160K), which abolishes BG1 binding and neutralization .

• Other V1V2-targeting antibodies: Include well-characterized V1V2 bNAbs like PG9 as comparative controls to assess relative binding patterns and neutralization potencies .

• Negative controls: Antibodies targeting non-overlapping epitopes (e.g., CD4bs antibodies) to confirm specificity of observed effects.

• Format controls: When comparing IgG versus Fab neutralization, include antibodies with known binding stoichiometry (e.g., PG9, which binds one Fab per trimer) to properly interpret molar neutralization ratios .

• Glycan-dependent binding controls: Include tests with glycosidase-treated Env or glycan-knockout variants to evaluate the contribution of specific glycans to BG1 binding .

These controls help to accurately interpret the specificity, mode of action, and comparative effectiveness of BG1 in experimental settings.

How can the asymmetric binding mode of BG1 be accurately visualized and analyzed?

Visualizing and analyzing the asymmetric binding mode of BG1 requires specialized approaches:

• Cryo-electron microscopy (cryo-EM): The primary method used to resolve the asymmetric binding of BG1 to HIV-1 Env trimer. For optimal results:

  • Use stabilized, soluble Env trimers (e.g., SOSIP.664 constructs)

  • Prepare grids with a mixture of Fab and trimer at appropriate ratios (e.g., 9:1 molar excess of Fab)

  • Collect and process data specifically looking for asymmetric features rather than imposing symmetry during reconstruction

  • Compare 2D class averages and 3D reconstructions with those of known symmetrically binding antibodies

• Classification of particle images: Use 3D classification without imposing symmetry to separate complexes with different stoichiometries (e.g., 2:1 versus 3:1 BG1:Env complexes) .

• Binding stoichiometry verification: Complement structural studies with biophysical methods such as size-exclusion chromatography with multi-angle light scattering (SEC-MALS) or isothermal titration calorimetry (ITC) to independently confirm binding stoichiometry .

• Molecular dynamics simulations: To understand the dynamic aspects of the asymmetric binding and potential conformational changes in Env induced by BG1 binding.

The current understanding of BG1's asymmetric binding comes from cryo-EM studies at 6.2 Å resolution, which showed that two BG1 Fabs bind to the Env trimer with distinct binding angles .

How might BG1-like antibodies contribute to new strategies for HIV prevention or therapy?

The unique properties of BG1 offer several potential avenues for HIV prevention or therapy:

• Antibody combinations: BG1 could be combined with antibodies targeting non-overlapping epitopes (e.g., BG18 targeting glycan-V3 and NC37 targeting CD4bs) to create broadly neutralizing cocktails. When tested in a 118-virus panel, a 1:1:1 mix of these three bNAbs neutralized 81% of viruses with a geometric mean IC50 of 0.130 μg/ml .

• Engineered antibodies: The unique binding mode of BG1 might inform the design of bispecific or multispecific antibodies that combine BG1-like V1V2 recognition with targeting of other vulnerable epitopes.

• Less mutated alternatives: BG1's relatively compact CDRH3 and distinct binding mode suggest the possibility of engineering simpler antibodies targeting the V1V2 epitope, potentially requiring less somatic hypermutation than other bNAbs .

• Passive immunization studies: BG1 could be included in passive immunization studies in combination with other bNAbs to evaluate protection against HIV-1 acquisition or control of established infection.

• Structure-guided immunogen design: The molecular details of BG1 recognition of V1V2 provide templates for designing immunogens that might elicit similar antibodies through vaccination .

These approaches leverage BG1's unique structural and functional properties to develop new strategies against HIV-1 that might overcome limitations of existing approaches.

What is the relationship between BG1's binding mode and viral escape mechanisms?

Understanding the relationship between BG1's binding mode and viral escape provides insights into HIV-1 evolution under antibody pressure:

• Glycan shield modifications: BG1's sensitivity to glycosylation at PNGS 130 suggests that addition or modification of glycans at this position represents a primary escape route for HIV-1 . Monitoring viral evolution in the presence of BG1 could reveal patterns of glycan shield remodeling.

• V1V2 sequence diversity: BG1's binding to V1V2 protein residues makes it vulnerable to escape through sequence changes in this region. Analysis of viral sequences from individuals with BG1-like antibodies could identify common escape mutations.

• Quaternary epitope disruption: Since BG1 binding involves interactions with glycans from neighboring protomers in the Env trimer , alterations in trimer structure or stability could constitute escape mechanisms that warrant investigation.

• Comparison with other V1V2 bNAbs: Comparing escape pathways from BG1 versus other V1V2-targeting antibodies (e.g., PG9) could reveal how different binding modes select for different escape variants.

• Compensatory mutations: Research could explore whether escape from BG1 requires compensatory mutations to maintain viral fitness, which could reveal constraints on viral evolution and potential vulnerabilities.

Detailed studies of viral evolution in the presence of BG1 would enhance our understanding of the interplay between antibody recognition and viral escape, potentially informing both vaccine design and therapeutic strategies.